Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PUR1800 | COPD
Previous Study | Return to List | Next Study

A Phase 1b Study of PUR1800 in Patients With COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04759807
Recruitment Status : Recruiting
First Posted : February 18, 2021
Last Update Posted : July 28, 2021
Sponsor:
Information provided by (Responsible Party):
Pulmatrix Inc.

Brief Summary:

This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs. Subjects will be randomised to one of the following 3 treatment sequences:

Sequence Period 1 Period 2 Period 3

  1. Placebo PUR1800 250 μg PUR1800 500 μg
  2. PUR1800 250 μg Placebo PUR1800 500 μg
  3. PUR1800 250 μg PUR1800 500 μg Placebo

Since this is the first study in humans in which the iSPERSE formulation is being administered, the 3 treatment sequences are designed in order to ensure that the lower dose of PUR1800 (250 μg) is administered prior to the administration of the higher dose of PUR1800 (500 μg).


Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Placebo Comparator Drug: PUR1800 250 ug Drug: PUR1800 500 ug Phase 1

Detailed Description:

The study design is as follows

Informed Consent: Before any study specific procedures are conducted or study requirements are expected of a patient, the patient must review and sign an IEC-approved informed consent form.

Screening: Subjects will be screened for eligibility to participate in the study within 28 days before randomisation (i.e. TP1, Day 1).

Treatment Periods:

Period 1: On Day 1 all subjects who are eligible for entry into the study will be randomised to 1 of 3 treatment sequences and receive either placebo or the lowest nominal dose of PUR1800 (PUR1800 250 μg) for 14 consecutive days.

Period 2: Following a washout period of at least 28 days after the completion of Period 1 dosing, subjects will receive a treatment other than what the subject received during Period 1 for 14 consecutive days.

Period 3: Following a washout period of at least 28 days after the completion of Period 2 dosing, subjects will receive the treatment that the subject had not received during Periods 1 or 2 (either placebo or PUR1800, 500 μg) for 14 consecutive days.

End of Study (EOS): Subjects will return to the study site 28 days after the last dose of the last TP (or in the event of early withdrawal after the last dose received, if possible) for an EOS visit. Unscheduled visits are permitted at the discretion of the investigator.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs. Subjects will be randomised to one of the following 3 treatment sequences: Sequence Period 1 Period 2 Period 3

  1. Placebo PUR1800 250 μg PUR1800 500 μg
  2. PUR1800 250 μg Placebo PUR1800 500 μg
  3. PUR1800 250 μg PUR1800 500 μg Placebo
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: A computerised randomisation scheme will be created and shall be considered blinded. The randomisation is available only to the clinical research unit pharmacy staff that are preparing the drug who will not be involved in any other aspect of the study including administration of the drug. It will not be made available to the subjects, site(s) PI(s), or members of the staff responsible for the monitoring and evaluation of safety assessments. PUR1800 and placebo capsules will be of the same shape, size, and color to ensure that the blind is maintained. A subject's treatment assignment will only be unblinded when knowledge of the treatment is essential for the further clinical management of the subject on this study or may potentially impact the safety of subjects currently enrolled or subjects in subsequent enrollment.
Primary Purpose: Treatment
Official Title: A Phase 1b 3-way Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Once Daily Doses of PUR1800 in Adult Patients With Stable Chronic Obstructive Pulmonary Disease
Actual Study Start Date : January 4, 2021
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : July 31, 2021

Arm Intervention/treatment
Placebo Comparator: Placebo
The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
Drug: Placebo Comparator
The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.

Active Comparator: PUR1800 250 μg
The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Drug: PUR1800 250 ug
The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.

Active Comparator: PUR1800 500 μg
The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Drug: PUR1800 500 ug
The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events adult patients with stable COPD. [ Time Frame: Day 1 through Day 28 ]
    Review of adverse events

  2. Incidence of intraday FEV1 declines (from pre-dose to post-dose) of ≥10%, ≥15%, and ≥20% adult patients with stable COPD. [ Time Frame: Day 1 through Day 28 ]
    Review of spirometry data

  3. Respiratory rate [ Time Frame: Day 1 through Day 28 ]
    Breaths per minute

  4. Blood presuure [ Time Frame: Day 1 through Day 28 ]
    Systolic pressure over diastolic pressure

  5. Heart rate [ Time Frame: Day 1 through Day 28 ]
    Beats per minute

  6. Oxygen saturation [ Time Frame: Day 1 through Day 28 ]
    As a percentage

  7. Medical history findings [ Time Frame: Day 1 through Day 28 ]
    Medical record review

  8. Physical examination findings [ Time Frame: Day 1 through Day 28 ]
    Physician's notes

  9. Clinical laboratory parameters [ Time Frame: Day 1 through Day 28 ]
    Lab reports with any out of range results flagged

  10. 12-Lead ECG findings [ Time Frame: Day 1 through Day 28 ]
    ECG report and tracing

  11. Occurrence of PEFR decline of ≥ 30% from the established baseline PEFR [ Time Frame: Day 1 through Day 28 ]
    Review of spirometry data

  12. Occurrence of administration of more than 12 inhalations of salbutamol per day over two consecutive days [ Time Frame: Day 1 through Day 28 ]
    Review of concomitant medications administered


Secondary Outcome Measures :
  1. AUC0-t [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  2. AUCinf inhaled PUR1800 in adult patients with stable COPD. [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  3. CL [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  4. Vss [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  5. t1/2 [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  6. Cmax [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  7. tmax [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken

  8. Accumulation factor [ Time Frame: Day 1 through Day 14 ]
    Derived from plasma PK samples taken


Other Outcome Measures:
  1. Sputum RV1162 concentration [ Time Frame: at trough on Days 2, 7, 14, and at the baseline visits prior to TP2 and TP3 as well as the EOS visit after TP3. ]
    From sputum samples obtained from subject through sputum induction



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet all the following:

  1. Male or female patients aged 40 to 75 years of age with a body mass index

    ≥ 17 and ≤ 35 kg/m2.

  2. Female patients must be either of non-childbearing potential or if of childbearing potential use a highly effective birth control method (See Section 9.4.1).
  3. Male patients with female partners of childbearing potential must be vasectomised with documented medical assessment of the surgical success or use highly effective contraception together with their female partner(s) (See Section 9.4.1).
  4. Female patients must agree not to donate ova/oocytes during the study and for 30 days after the last dose of IMP.
  5. Male patients must agree not to donate semen during the study and for 90 days after the last dose of IMP.
  6. Confirmed diagnosis by a physician of COPD with symptoms compatible with COPD for at least 1 year prior to screening.
  7. Severity of Disease: patients who conform to the current severity classification for GOLD Grade II/III disease in terms of post-bronchodilator spirometry at screening: Post-salbutamol FEV1/FVC ratio of < 0.70. Post-salbutamol FEV1 ≥ 40 % and ≤ 80 % of predicted normal values (based on the Global Lung Function Initiative [GLI-2012][1]).
  8. Current or previous tobacco smoker with a smoking history of ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or equivalent).
  9. Vital signs recorded from automated blood pressure equipment within the following normal ranges: Blood pressure; systolic value of 90 mmHg to 160 mmHg, diastolic value of 60 mmHg to 90 mmHg and pulse rate ≥ 60 and

    ≤100 beats per minute at screening and prior to randomisation.

  10. Able to provide written Informed Consent Form (ICF) prior to participation in any study-related activities, and to comply with the requirements of the study.
  11. Able to perform technically acceptable spirometry at screening.
  12. Able to produce a sputum sample of adequate quality at either the Screening or Baseline visit prior to randomisation.
  13. Able to demonstrate the correct inhalation technique for use of the delivery device and to generate sufficient peak inspiratory flow (PIF) (at least 40 L/min) using the In-Check DIAL device at screening and prior to randomisation.

Exclusion Criteria:

Patients who meet any of the following are not eligible:

  1. Upper or lower respiratory tract infection within 6 weeks prior to screening or prior to randomisation.
  2. COPD exacerbation requiring oral steroids and/or antibiotics, within the 6 weeks prior to screening or prior to randomisation.
  3. Clinically significant abnormal laboratory values at screening that, in the opinion of the investigator would make the patient inappropriate for the study or put the patient at undue risk, specifically liver function tests (LFTs: aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transferase [GGT], total bilirubin) >3 x upper limit of normal (ULN); hemoglobin <10 gm/dL; absolute neutrophil count (ANC) <1000; white blood cells (WBC) >20,000; Platelets <100,000 and >500,000; prothrombin time (PT) >14 seconds.
  4. QTcF of >450 msec in males or >470 msec in females on any of the three individual ECG measurements at screening or prior to randomisation.
  5. History of drug or alcohol abuse within the past 2 years prior to screening or prior to randomisation.
  6. History of regular alcohol consumption within 6 months prior to screening or prior to randomisation defined as an average weekly intake of >21 units for males, or >14 units for females, where one unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  7. Positive alcohol breath test result at screening or prior to randomisation.
  8. Positive urine drugs of abuse test result (unless in the opinion of the investigator this can be explained by the patient's current medications) at screening or prior to randomisation; unexpected or unexplained positive results may require discussion with Sponsor.
  9. Current users of e-cigarettes and those who have used these products within one month prior to screening or between screening and randomisation.
  10. Known sensitivity to the study drug or any of the excipients of the formulation, or history of clinically significant sensitivity to any agent that, in the opinion of the investigator, would make participation in the study inadvisable.
  11. Donated blood or blood products or had substantial loss of blood (more than 500 mL) within 3 months before the first administration of study drug, or intention to donate blood or blood products during the study.
  12. Participated in an interventional study involving an experimental therapeutic agent within 3 months of screening or prior to randomisation.
  13. Women who have a positive serum β-human chorionic gonadotropin (hCG) pregnancy test at screening or a positive urinary hCG pregnancy test prior to randomisation, is pregnant, lactating, or planning to become pregnant during the study.
  14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or HIV results. Patients who are HBs antibody positive or HB core antibody positive are not excluded provided the HBsAg result is negative. Patients who are HCV Ab positive are not excluded if a subsequent HCV RNA test is negative.
  15. Planned surgery or procedures during the participation of the study and for 28 days after the conclusion of study participation.
  16. Employee of the investigator or study centre with direct involvement in the proposed study or other studies under the direction of that investigator or study centre, as well as family members of the employees or the investigator.
  17. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  18. The patient is unable or unwilling to comply fully with the study protocol.
  19. Patient is mentally or legally incapacitated.
  20. Unable or unwilling to undergo multiple venepuncture procedures or the patient has poor access to veins suitable for cannulation.
  21. Any other reason that, in the opinion of the investigator, would make participation in the study inadvisable.
  22. A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation within the last 5 years.
  23. A history of > 1 hospitalisation for COPD in the previous 1 year prior to screening.
  24. Evidence of cor pulmonale or clinically significant pulmonary hypertension.
  25. Requires routine treatment for COPD using one (or more) of the following therapies within the 6 weeks before screening or prior to randomisation: Oral Beta-2 agonists Methyl xanthines Phosphodiesterase (PDE) inhibitors Oral leukotriene inhibitors Oral or parenteral glucocorticoids Antibiotic therapies for acute infections (Note: chronic antibiotic use for prophylaxis, e.g. macrolides, is acceptable).
  26. Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, known alpha-1 antitrypsin deficiency or other active pulmonary diseases other than COPD.
  27. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematologic, urologic, immunologic, or ophthalmic diseases that, in the opinion of the investigator, would make participation in the study inadvisable.
  28. Patients with a history of sleep apnoea requiring non-invasive ventilation or supplemental oxygen during sleep.
  29. Previous lung resection or lung reduction surgery.
  30. Active participation in a pulmonary rehabilitation program.
  31. Has had major surgery within 6 weeks prior to screening or prior to randomisation.
  32. A disclosed history, or one known to the Investigator, of significant noncompliance in previous investigational studies or with prescribed medications.
  33. History of unstable or uncontrolled hypertension or has been diagnosed with hypertension in last 3 months prior to screening or prior to randomisation.
  34. Requires supplemental oxygen, even on an occasional basis.
  35. Received a live vaccine within 6 weeks prior to screening or prior to randomisation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04759807


Contacts
Layout table for location contacts
Contact: Russell G. Clayton, DO 215-813-5100 rclayton@pulmatrix.com
Contact: Audrey Rossow 508-808-5489 arossow@pulmatrix.com

Locations
Layout table for location information
United Kingdom
Medicines Evaluation Unit Ltd. Recruiting
Manchester, Wythenshawe, United Kingdom, M23 9QZ
Contact: Kultaar Singh    +44 (0)161 359 7941    ksingh@meu.org.uk   
Contact: Rachael Leech    +44 (0)161 946 4088    Rleech@meu.org.uk   
Sponsors and Collaborators
Pulmatrix Inc.
Investigators
Layout table for investigator information
Principal Investigator: Dave Singh, Prof The Medicines Evaluation Unit
Layout table for additonal information
Responsible Party: Pulmatrix Inc.
ClinicalTrials.gov Identifier: NCT04759807    
Other Study ID Numbers: 601-0016
First Posted: February 18, 2021    Key Record Dates
Last Update Posted: July 28, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases